Citron Research Exposes Exact Sciences And Proves Beyond Any Doubt Why This Stock Will Soon Be Cut In Half

Citron Research profile picture
Citron Research


  • Citron has had great success exposing companies whose business model has been to take advantage of a “broken healthcare system” but this case is unique.
  • The key metrics not disclosed by Exact Sciences are getting worse.
  • Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.

This article was written by

Citron Research profile picture
Andrew Left's Citron Research ( (formally known as seeks to expose companies whose management is in some way misleading investors. Left digs into SEC filings, financials, management histories and other data to uncover such situations, and he is usually short the stocks he writes about. Mr. Left has been publishing for 7 years and has created a track record that is unrivaled in short selling. Mr. Left has been cited in Barron's, Wall St Journal, CNBC and other major publications repeatedly for his work. Mr. Left was also an invited speaker at the reknown Master Investor Conference. Visit: Citron Research (
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.